Oncternal Therapeutics, Inc. announced the receipt of a 'Study May Proceed' letter from the U.S. Food and Drug Administration (FDA), 30 days after submitting its Investigational New Drug (IND) application for a Phase 1/2 dose escalation study of ONCT-808, an autologous chimeric antigen receptor (CAR) T therapy targeting ROR1, in patients with aggressive B cell non-Hodgkin's lymphoma (B NHL), including those who have failed previous CD19 CAR T treatment.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.18 USD | +0.99% | -6.88% | -23.72% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-23.72% | 24.21M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- ONCT Stock
- News Oncternal Therapeutics, Inc.
- Oncternal Therapeutics Receives IND Clearance for ONCT-808, Its Autologous Car T Product Candidate Targeting Ror1 for the Treatment of Aggressive B Cell Lymphoma